Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Immunotherapy of Cancer Conference (ITOC) is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

ITOC 2022

The 9th Immunotherapy of Cancer Conference
22–24 September 2022 | Munich, Germany

ITOC 2022

The 9th Immunotherapy of Cancer Conference
22–24 September 2022 | Munich, Germany
The Immunotherapy of Cancer Conference (ITOC) is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.
Potentiating immunotherapy for bladder cancer via porphyrin-based PLZ4-nanoparticles 1:50
Potentiating immunotherapy for bladder cancer via porphyrin-based PLZ4-nanoparticles
Chong Xian Pan • 27 Sep 2022
Immunotherapy + chemotherapy for bladder cancer 0:28
Immunotherapy + chemotherapy for bladder cancer
Chong Xian Pan • 27 Sep 2022
The selection of PD-L1 escape variants in microsatellite stable metastatic CRC on avelumab treatment 3:59
The selection of PD-L1 escape variants in microsatellite stable metastatic CRC on avelumab treatment
Mascha Binder • 19 Sep 2022
CAR-T cells expressing a scFV targeting the hTSHR in thyroid cancer 2:39
CAR-T cells expressing a scFV targeting the hTSHR in thyroid cancer
Mascha Binder • 19 Sep 2022
The major hurdles of CAR-T cell therapy for solid tumors 0:41
The major hurdles of CAR-T cell therapy for solid tumors
Florian Märkl • 3 Oct 2022
Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanoma 2:11
Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanoma
Florian Märkl • 3 Oct 2022
The use of chemokines in cancer immunotherapy 1:58
The use of chemokines in cancer immunotherapy
Florian Märkl • 3 Oct 2022
ITOC 2022 highlights: B-cell engineering for cancer treatment 0:33
ITOC 2022 highlights: B-cell engineering for cancer treatment
Florian Märkl • 3 Oct 2022
Promoting the functional persistence of CAR-T cells in solid tumors via immune checkpoint blockade 2:01
Promoting the functional persistence of CAR-T cells in solid tumors via immune checkpoint blockade
Prasad Adusumilli • 27 Sep 2022
Armoring anti-HER2 CAR-T cells with CCR8 and a DNR to enable efficacy in solid tumor models 4:37
Armoring anti-HER2 CAR-T cells with CCR8 and a DNR to enable efficacy in solid tumor models
Thaddäus Strzalkowski • 29 Sep 2022
Challenges associated with CAR-T cells in solid tumors 1:28
Challenges associated with CAR-T cells in solid tumors
Thaddäus Strzalkowski • 29 Sep 2022
The synergistic antitumor activity of pan-PI3K inhibition and ICI’s in bladder cancer 1:36
The synergistic antitumor activity of pan-PI3K inhibition and ICI’s in bladder cancer
Chong Xian Pan • 29 Sep 2022
Addressing the unmet needs of immunotherapy in bladder cancer 0:54
Addressing the unmet needs of immunotherapy in bladder cancer
Chong Xian Pan • 29 Sep 2022
Overcoming the challenges faced with cellular therapies in solid tumors 3:10
Overcoming the challenges faced with cellular therapies in solid tumors
Sebastian Kobold • 27 Sep 2022
P329G-targeting CAR-T cells designed to target solid tumors 2:57
P329G-targeting CAR-T cells designed to target solid tumors
Sebastian Kobold • 27 Sep 2022
The use of RNA vaccines to promote CAR-T stimulation in solid tumors 2:02
The use of RNA vaccines to promote CAR-T stimulation in solid tumors
Sebastian Kobold • 27 Sep 2022
The content of VJOncology is intended for healthcare professionals